D.A. Davidson & Co’s Galectin Therapeutics GALT Stock Holding History

D.A. Davidson & Co’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,000	Closed	-$42.4K	–	1559
2025 Q3	$42.4K	Hold	10,000	–	–	﹤0.01%	1505
2025 Q2	$21.1K	Hold	10,000	–	–	﹤0.01%	1430
2025 Q1	$12.2K	Sell	10,000 -9,000	-47%	-$12.6K	﹤0.01%	1393
2024 Q4	$24.5K	Sell	19,000 -11,771	-38%	-$28.2K	﹤0.01%	1402
2024 Q3	$84.6K	Sell	30,771 -18,000	-37%	-$44.2K	﹤0.01%	1348
2024 Q2	$110K	Buy	48,771 +1,116	+2%	+$3.39K	﹤0.01%	1321
2024 Q1	$114K	Buy	47,655 +5,000	+12%	+$9.46K	﹤0.01%	1338
2023 Q4	$70.8K	Buy	42,655 +4,830	+13%	+$9.37K	﹤0.01%	1334
2023 Q3	$72.6K	Buy	37,825 +5,000	+15%	+$8.23K	﹤0.01%	1289
2023 Q2	$47.3K	Hold	32,825	–	–	﹤0.01%	1313
2023 Q1	$68.9K	Buy	32,825 +15	+0%	+$24	﹤0.01%	1307
2022 Q4	$37.1K	Hold	32,810	–	–	﹤0.01%	1287
2022 Q3	$53K	Sell	32,810 -12,525	-28%	-$23.4K	﹤0.01%	1253
2022 Q2	$59K	Sell	45,335 -9,975	-18%	-$14.3K	﹤0.01%	1247
2022 Q1	$89K	Hold	55,310	–	–	﹤0.01%	1260
2021 Q4	$114K	Sell	55,310 -2,000	-3%	-$5.71K	﹤0.01%	1234
2021 Q3	$222K	Sell	57,310 -4,000	-7%	-$13.6K	﹤0.01%	1118
2021 Q2	$196K	Sell	61,310 -4,000	-6%	-$14.2K	﹤0.01%	1134
2021 Q1	$142K	Sell	65,310 -702,011	-91%	-$1.57M	﹤0.01%	1108
2020 Q4	$1.72M	Sell	767,321 -86,395	-10%	-$227K	0.03%	375
2020 Q3	$2.28M	Buy	853,716 +2,615	+0.3%	+$7.32K	0.04%	292
2020 Q2	$2.6M	Buy	851,101 +12,836	+2%	+$32.3K	0.05%	259
2020 Q1	$1.64M	Sell	838,265 -2,683	-0.3%	-$6.53K	0.03%	356
2019 Q4	$2.4M	Buy	840,948 +20,790	+3%	+$72.2K	0.04%	329
2019 Q3	$3.01M	Buy	820,158 +29,284	+4%	+$106K	0.05%	269
2019 Q2	$3.28M	Buy	790,874 +36,519	+5%	+$158K	0.06%	239
2019 Q1	$3.85M	Buy	754,355 +35,432	+5%	+$170K	0.07%	231
2018 Q4	$2.47M	Buy	718,923 +29,645	+4%	+$142K	0.05%	290
2018 Q3	$4.14M	Buy	689,278 +32,751	+5%	+$180K	0.07%	220
2018 Q2	$4.17M	Sell	656,527 -74,773	-10%	-$364K	0.08%	207
2018 Q1	$3.47M	Buy	731,300 +43,147	+6%	+$201K	0.07%	226
2017 Q4	$2.3M	Sell	688,153 -2,807	-0.4%	-$7.1K	0.05%	296
2017 Q3	$1.48M	Sell	690,960 -47,540	-6%	-$94.2K	0.03%	422
2017 Q2	$1.82M	Sell	738,500 -62,090	-8%	-$165K	0.04%	330
2017 Q1	$1.84M	Buy	800,590 +76,167	+11%	+$115K	0.04%	314
2016 Q4	$709K	Buy	724,423 +121,692	+20%	+$108K	0.02%	559
2016 Q3	$681K	Buy	602,731 +33,382	+6%	+$59.3K	0.02%	550
2016 Q2	$836K	Buy	569,349 +148,539	+35%	+$218K	0.02%	431
2016 Q1	$601K	Buy	420,810 +49,909	+13%	+$67K	0.02%	486
2015 Q4	$608K	Buy	370,901 +58,015	+19%	+$133K	0.02%	490
2015 Q3	$732K	Buy	312,886 +171,305	+121%	+$404K	0.03%	446
2015 Q2	$386K	Buy	141,581 +11,081	+8%	+$33.4K	0.01%	646
2015 Q1	$437K	Buy	130,500 +10,000	+8%	+$35.7K	0.01%	611
2014 Q4	$418K	Buy	120,500 +900	+0.8%	+$3.98K	0.01%	633
2014 Q3	$601K	Sell	119,600 -74,558	-38%	-$581K	0.02%	534
2014 Q2	$2.68M	Buy	194,158 +43,515	+29%	+$542K	0.09%	227
2014 Q1	$2.31M	Sell	150,643 -42,307	-22%	-$602K	0.08%	243
2013 Q4	$1.56M	Buy	+192,950	New	+$1.78M	0.06%	291

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

D.A. Davidson & Co's GALT Position: Q4 2025 in Review

D.A. Davidson & Co sold out of Galectin Therapeutics (GALT) in Q4 2025, closing a stake of 10,000 shares — an estimated $42.4K sold.

D.A. Davidson & Co first reported a position in GALT in Q4 2013 and held it in 48 quarters. The position peaked at $4.17M in Q2 2018. 97 funds tracked by Wall St. Rank hold GALT as of Q4 2025.

D.A. Davidson & Co reported no remaining Galectin Therapeutics position as of Q4 2025 after selling out during the quarter.
D.A. Davidson & Co sold 10,000 Galectin Therapeutics shares in Q4 2025, an estimated $42.4K.
D.A. Davidson & Co first reported a position in Galectin Therapeutics in Q4 2013 and held it in 48 quarters.
D.A. Davidson & Co's Galectin Therapeutics position peaked at $4.17M in Q2 2018.
97 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2025.

Based on D.A. Davidson & Co's 13F filing for Q4 2025, filed 29 Jan 2026.